Kantsadi Anastassia L, Stravodimos George A, Kyriakis Efthimios, Chatzileontiadou Demetra S M, Solovou Theodora G A, Kun Sándor, Bokor Éva, Somsák László, Leonidas Demetres D
Department of Biochemistry and Biotechnology, University of Thessaly, Biopolis, 41500 Larissa, Greece.
Department of Organic Chemistry, University of Debrecen, POB 400, H-4002 Debrecen, Hungary.
J Struct Biol. 2017 Jul;199(1):57-67. doi: 10.1016/j.jsb.2017.05.001. Epub 2017 May 5.
3-(C-Glucopyranosyl)-5aryl-1,2,4-triazoles with an aryl moiety larger than phenyl have been shown to have strong inhibitory potency (K values in the range of upper nM) for human liver glycogen phosphorylase (hlGP), a pharmacologically relevant target for diabetes type 2. In this study we investigate in a comparative manner the inhibitory effect of the above triazoles and their respective imidazoles on hlGPa. Kinetic studies show that the imidazole derivatives are 6-8 times more potent than their corresponding triazoles. We also seek to answer how the type of the aryl moiety affects the potency in hlGPa, and by determination of the crystal structure of rmGPb in complex with the triazole derivatives the structural basis of their inhibitory efficacy is also elucidated. Our studies revealed that the van der Waals interactions between the aryl moiety and residues in a hydrophobic pocket within the active site are mainly responsible for the variations in the potency of these inhibitors.
已证明,芳基部分大于苯基的3-(C-吡喃葡萄糖基)-5-芳基-1,2,4-三唑对人肝糖原磷酸化酶(hlGP)具有很强的抑制效力(K值在上nM范围内),hlGP是2型糖尿病的一个药理学相关靶点。在本研究中,我们以比较的方式研究上述三唑及其各自的咪唑对hlGPa的抑制作用。动力学研究表明,咪唑衍生物的效力比其相应的三唑高6-8倍。我们还试图回答芳基部分的类型如何影响hlGPa中的效力,并且通过测定与三唑衍生物复合的rmGPb的晶体结构,也阐明了它们抑制效力的结构基础。我们的研究表明,芳基部分与活性位点内疏水口袋中的残基之间的范德华相互作用是这些抑制剂效力变化的主要原因。